Axial Involvement in Psoriatic Arthritis cohort (AXIS): the protocol of a joint project of the Assessment of SpondyloArthritis international Society (ASAS) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)

1. Prey, S, Paul, C, Bronsard, V, et al. Assessment of risk of psoriatic arthritis in patients with plaque psoriasis: a systematic review of the literature. J Eur Acad Dermatol Venereol 2010; 24(Suppl. 2): 31–35.
Google Scholar | Crossref | Medline2. Alinaghi, F, Calov, M, Kristensen, LE, et al. Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol 2019; 80: 251–265.e219.
Google Scholar | Crossref | Medline3. Gladman, DD, Shuckett, R, Russell, ML, et al. Psoriatic arthritis (PSA) – an analysis of 220 patients. Q J Med 1987; 62: 127–141.
Google Scholar | Medline4. Gladman, DD . Axial disease in psoriatic arthritis. Curr Rheumatol Rep 2007; 9: 455–460.
Google Scholar | Crossref | Medline5. Chandran, V . Psoriatic spondylitis or ankylosing spondylitis with psoriasis: same or different? Curr Opin Rheumatol 2019; 31: 329–334.
Google Scholar | Crossref | Medline6. Jadon, DR, Sengupta, R, Nightingale, A, et al. Axial disease in psoriatic arthritis study: defining the clinical and radiographic phenotype of psoriatic spondyloarthritis. Ann Rheum Dis 2017; 76: 701–707.
Google Scholar | Crossref | Medline7. Feld, J, Ye, JY, Chandran, V, et al. Axial disease in psoriatic arthritis: the presence and progression of unilateral grade 2 sacroiliitis in a psoriatic arthritis cohort. Semin Arthritis Rheum 2021; 51: 464–468.
Google Scholar | Crossref | Medline8. Mease, PJ, Palmer, JB, Liu, M, et al. Influence of axial involvement on clinical characteristics of psoriatic arthritis: analysis from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. J Rheumatol 2018; 45: 1389–1396.
Google Scholar | Crossref | Medline9. Taylor, W, Gladman, D, Helliwell, P, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006; 54: 2665–2673.
Google Scholar | Crossref | Medline10. Rudwaleit, M, van der Heijde, D, Landewe, R, et al. The Assessment of SpondyloArthritis international Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 2011; 70: 25–31.
Google Scholar | Crossref | Medline | ISI11. Feld, J, Ye, JY, Chandran, V, et al. Is axial psoriatic arthritis distinct from ankylosing spondylitis with and without concomitant psoriasis? Rheumatology 2020; 59: 1340–1346.
Google Scholar | Crossref | Medline12. Feld, J, Chandran, V, Haroon, N, et al. Axial disease in psoriatic arthritis and ankylosing spondylitis: a critical comparison. Nat Rev Rheumatol 2018; 14: 363–371.
Google Scholar | Crossref | Medline13. Haroon, M, Ahmad, M, Baig, MN, et al. Inflammatory back pain in psoriatic arthritis is significantly more responsive to corticosteroids compared to back pain in ankylosing spondylitis: a prospective, open-labelled, controlled pilot study. Arthritis Res Ther 2018; 20: 73.
Google Scholar | Crossref | Medline14. Baraliakos, X, Gossec, L, Pournara, E, et al. Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial. Ann Rheum Dis 2021; 80: 582–590.
Google Scholar | Crossref | Medline15. Deodhar, A, Gensler, LS, Sieper, J, et al. Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis. Arthritis Rheumatol 2019; 71: 258–270.
Google Scholar | Crossref | Medline16. Baeten, D, Østergaard, M, Wei, JC, et al. Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study. Ann Rheum Dis 2018; 77: 1295–1302.
Google Scholar | Crossref | Medline17. Gottlieb, A, Menter, A, Mendelsohn, A, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 2009; 373: 633–640.
Google Scholar | Crossref | Medline | ISI18. Gordon, KB, Strober, B, Lebwohl, M, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet 2018; 392: 650–661.
Google Scholar | Crossref | Medline19. Mease, P, Helliwell, P, Gladman, D, et al. Efficacy of guselkumab, a monoclonal antibody that specifically binds the p19 subunit of IL-23, on axial involvement in patients with active PsA with sacroiliitis: post-hoc analyses through week 52 from the phase 3, randomized, double-blind, placebo-controlled DISCOVER Studies. Lancet Rheumatol 2021; 3: e715–e723.
Google Scholar20. Maksymowych, WP, Mallon, C, Morrow, S, et al. Development and validation of the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index. Ann Rheum Dis 2009; 68: 948–953.
Google Scholar | Crossref | Medline21. Heuft-Dorenbosch, L, Spoorenberg, A, van Tubergen, A, et al. Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis 2003; 62: 127–132.
Google Scholar | Crossref | Medline22. Healy, PJ, Helliwell, PS. Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis. Arthritis Rheum 2008; 59: 686–691.
Google Scholar | Crossref | Medline23. Jenkinson, TR, Mallorie, PA, Whitelock, HC, et al. Defining spinal mobility in ankylosing spondylitis (AS). J Rheumatol 1994; 21: 1694–1698.
Google Scholar | Medline | ISI24. van der Heijde, D, Landewe, R, Feldtkeller, E. Proposal of a linear definition of the Bath Ankylosing Spondylitis Metrology Index (BASMI) and comparison with the 2-step and 10-step definitions. Ann Rheum Dis 2008; 67: 489–493.
Google Scholar | Crossref | Medline25. Cauli, A, Gladman, DD, Mathieu, A, et al. Patient global assessment in psoriatic arthritis: a multicenter GRAPPA and OMERACT study. J Rheumatol 2011; 38: 898–903.
Google Scholar | Crossref | Medline26. Fries, JF, Spitz, P, Kraines, RG, et al. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 137–145.
Google Scholar | Crossref | Medline27. Daltroy, LH, Larson, MG, Roberts, NW, et al. A modification of the Health Assessment Questionnaire for the spondyloarthropathies. J Rheumatol 1990; 17: 946–950.
Google Scholar | Medline28. Gossec, L, de Wit, M, Kiltz, U, et al. A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. Ann Rheum Dis 2014; 73: 1012–1019.
Google Scholar | Crossref | Medline | ISI29. Garrett, S, Jenkinson, T, Kennedy, LG, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994; 21: 2286–2291.
Google Scholar | Medline | ISI30. Calin, A, Garrett, S, Whitelock, H, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994; 21: 2281–2285.
Google Scholar | Medline | ISI31. Kiltz, U, van der Heijde, D, Boonen, A, et al. Development of a health index in patients with ankylosing spondylitis (ASAS HI): final result of a global initiative based on the ICF guided by ASAS. Ann Rheum Dis 2015; 74: 830–835.
Google Scholar | Crossref | Medline32. Reilly, MC, Zbrozek, AS, Dukes, EM. The validity and reproducibility of a work productivity and activity impairment instrument. PharmacoEconomics 1993; 4: 353–365.
Google Scholar | Crossref | Medline | ISI33. Daniel, WW, Cross, CL. Biostatistics: a foundation for analysis in the health sciences. New York: Wiley, 2018.
Google Scholar

留言 (0)

沒有登入
gif